In GBM, gain-of-function mutations in the IDH1 gene lead to increased production of oncometabolites such as 2-hydroxyglutaric acid (2-HG), which inhibit histone demethylases and the TET family of 5-methycytosine (5mC) hydroxylases. This evidence concerns the gene IDH1 and glioblastoma.